Equities Analysts Issue Forecasts for Exelixis Q3 Earnings

Key Points

• William Blair has raised its Q3 2025 earnings per share estimate for Exelixis from $0.58 to $0.63, maintaining an "Outperform" rating on the stock.
• Exelixis reported Q2 earnings of $0.75 per share, exceeding analysts' expectations of $0.63, despite a revenue decline of 10.8% year-over-year.
• Institutional investors own about 85.27% of Exelixis' stock, indicating strong backing from larger investment firms.

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Analysts at William Blair lifted their Q3 2025 earnings per share estimates for Exelixis in a research report issued to clients and investors on Tuesday, July 29th. William Blair analyst A. Hsieh now expects that the biotechnology company will earn $0.63 per share for the quarter, up from their prior estimate of $0.58. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Exelixis' current full-year earnings is $2.04 per share. William Blair also issued estimates for Exelixis' Q4 2025 earnings at $0.60 EPS, FY2025 earnings at $2.43 EPS, Q1 2026 earnings at $0.56 EPS, Q2 2026 earnings at $0.56 EPS, Q3 2026 earnings at $0.57 EPS, Q4 2026 earnings at $0.58 EPS and FY2026 earnings at $2.28 EPS.

EXEL has been the topic of several other research reports. Citigroup increased their target price on Exelixis from $45.00 to $56.00 and gave the company a "buy" rating in a research report on Thursday, May 15th. Jefferies Financial Group set a $50.00 target price on Exelixis and gave the company a "buy" rating in a research report on Tuesday, June 24th. Benchmark reaffirmed a "neutral" rating on shares of Exelixis in a research report on Monday, June 23rd. Morgan Stanley decreased their price objective on Exelixis from $48.00 to $46.00 and set an "overweight" rating for the company in a report on Tuesday, July 29th. Finally, UBS Group set a $38.00 price objective on Exelixis and gave the company a "neutral" rating in a report on Wednesday, July 30th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $44.44.

Exelixis Price Performance

NASDAQ EXEL traded up $0.59 during midday trading on Friday, hitting $37.40. 2,089,020 shares of the company traded hands, compared to its average volume of 3,093,872. The company has a market cap of $10.07 billion, a PE ratio of 17.98, a price-to-earnings-growth ratio of 0.77 and a beta of 0.29. The company's 50-day simple moving average is $42.82 and its 200-day simple moving average is $38.93. Exelixis has a 52 week low of $23.21 and a 52 week high of $49.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.12. The business had revenue of $568.26 million for the quarter, compared to analysts' expectations of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%. The business's revenue for the quarter was down 10.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.84 EPS.

Insider Buying and Selling

In other Exelixis news, CFO Christopher J. Senner sold 100,000 shares of the stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $46.00, for a total transaction of $4,600,000.00. Following the sale, the chief financial officer directly owned 967,842 shares of the company's stock, valued at approximately $44,520,732. This trade represents a 9.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Stelios Papadopoulos sold 36,508 shares of the stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $44.35, for a total value of $1,619,129.80. Following the sale, the director directly owned 1,279,416 shares in the company, valued at $56,742,099.60. This represents a 2.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 456,605 shares of company stock worth $20,966,005 over the last three months. Corporate insiders own 2.85% of the company's stock.

Institutional Investors Weigh In On Exelixis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its position in shares of Exelixis by 32.2% during the 1st quarter. GAMMA Investing LLC now owns 5,457 shares of the biotechnology company's stock valued at $201,000 after acquiring an additional 1,328 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Exelixis during the 4th quarter valued at about $17,046,000. Wells Fargo & Company MN grew its position in shares of Exelixis by 1,637.9% during the 4th quarter. Wells Fargo & Company MN now owns 746,286 shares of the biotechnology company's stock valued at $24,851,000 after acquiring an additional 703,343 shares during the period. Park Avenue Securities LLC grew its position in shares of Exelixis by 10.6% during the 1st quarter. Park Avenue Securities LLC now owns 7,358 shares of the biotechnology company's stock valued at $272,000 after acquiring an additional 707 shares during the period. Finally, Envestnet Asset Management Inc. grew its position in shares of Exelixis by 23.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 248,073 shares of the biotechnology company's stock valued at $9,159,000 after acquiring an additional 47,845 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.